We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Crossject | EU:ALCJ | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 1.91% | 2.67 | 2.64 | 2.67 | 2.70 | 2.62 | 2.65 | 83,651 | 16:40:00 |
Dijon, France, July 15th 2024, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE®, its emergency treatment for the management of epileptic crises based on its award-winning needle-free auto-injector ZENEO®, announces it will attend the H.C. Wainwright 26th Annual Global Investment Conference, taking place in New York September 9-11, 2024.
About Crossject
Crossject SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharma companybased in France and the U.S. It is in advanced regulatory development for ZEPIZURE®, anepileptic rescue therapy, for which it was awarded a $60 million contract with the U.S.Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company’s award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscularinjection on bare skin or even through clothing. The Company’s other products in developmentinclude rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthmaattacks.
For further information, please contact:
Investors Natasha DrapeauCohesion Bureau+41 76 823 75 27natasha.drapeau@cohesionbureau.com | MediaSophie BaumontCohesion Bureau+33 6 27 74 74 49sophie.baumont@cohesionbureau.com |
Attachment
1 Year Crossject Chart |
1 Month Crossject Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions